Company Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 16, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Anhco Nguyen |
Contact Details
Address: 2380 Conejo Spectrum Street, Suite 200 Thousand Oaks, California 91320 United States | |
| Phone | 805 623 4211 |
| Website | atarabio.com |
Stock Details
| Ticker Symbol | ATRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604464 |
| CUSIP Number | 046513107 |
| ISIN Number | US0465131078 |
| Employer ID | 46-0920988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anhco Nguyen Ph.D. | President, Chief Executive Officer and Director |
| Eric Hyllengren | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
| Alex Chapman | Vice President of Corporate Communications and Investor Relations |
| Jill Henrich | Executive Vice President and Global Head of Regulatory Affairs and Quality |
| Dan Maziasz | Executive Vice President and Chief Business Officer |
| Rajani Dinavahi M.D. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 6, 2025 | SCHEDULE 13G | Filing |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Jan 17, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 16, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 144 | Filing |
| Nov 18, 2024 | 144 | Filing |
| Nov 18, 2024 | 144 | Filing |
| Nov 18, 2024 | 144 | Filing |